Page last updated: 2024-12-05

2-ethylhexanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Ethylhexanoic acid, also known as 2-ethylbutyric acid, is a colorless liquid with a pungent odor. It is a carboxylic acid with the formula CH3CH2CH(C2H5)CH2COOH. This compound is a common industrial chemical used as an intermediate in the production of various materials, including plasticizers, lubricants, and surfactants. It is also used as a catalyst in some chemical reactions. 2-Ethylhexanoic acid can be synthesized through several methods, including the oxidation of 2-ethylhexanol. The acid is biodegradable and generally considered to be relatively safe, but exposure to high concentrations can cause skin and eye irritation. Due to its versatility and importance in chemical synthesis, 2-ethylhexanoic acid is frequently studied for its properties and potential applications in various industries.'

2-ethylhexanoic acid: structure in first source; wood preservative; 2-ethylhexanoic acid is active ingredient in Sinesto B [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8697
CHEMBL ID1162485
CHEBI ID89058
SCHEMBL ID25800
MeSH IDM0120998

Synonyms (86)

Synonym
AKOS009031416
EN300-20410
hexanoic acid, 2-ethyl-, (-)-
2-ethylhexoic acid
ethylhexoic acid
wln: qvy4 & 2
ethylhexanoic acid
hexanoic acid, 2-ethyl-
nsc-8881
.alpha.-ethylhexanoic acid
3-heptanecarboxylic acid
2-ethylhexanoic acid
butylethylacetic acid
nsc8881
.alpha.-ethylcaproic acid
149-57-5
2-ethylcaproic acid
2-butylbutanoic acid
NCGC00091324-01
ai3-01371
kyselina 2-ethylkapronova [czech]
alpha-ethylcaproic acid
2-ethylhexansaeure
ccris 3348
ethyl hexanoic acid, 2-
hsdb 5649
kyselina heptan-3-karboxylova [czech]
ethyl hexanoic acid
nsc 8881
brn 1750468
einecs 205-743-6
2-ethylhexanoic acid, >=99%
2-ethylhexanoic acid, 99%
2-ethylhexanoic acid, analytical standard
alpha-ethyl caproic acid
2-ethyl-hexanoic acid
2-ethyl-hexoic acid
LMFA01020087
smr001252268
MLS002415695
18FEB650-7573-4EA0-B0CD-9D8BED766547
(+/-)-2-ethylhexanoic acid
FT-0654390
E0120
chebi:89058 ,
CHEMBL1162485
NCGC00091324-03
NCGC00091324-02
cas-149-57-5
NCGC00253985-01
tox21_201406
dtxsid9025293 ,
NCGC00258957-01
tox21_300108
dtxcid805293
2-ethyl hexanoic acid
HMS2267F21
einecs 262-971-9
61788-37-2
2-ethylcapronic acid
kyselina heptan-3-karboxylova
kyselina 2-ethylkapronova
ec 205-743-6
unii-01mu2j7vvz
01mu2j7vvz ,
FT-0612273
2-ethylhexanoic acid [hsdb]
2-ethyl-1-hexanoic acid
SCHEMBL25800
STR05759
W-109079
mfcd00002675
F0001-0703
2 ethyl hexanoic acid
AT29893
2-ethyl hexoic acid,ar
2-ethylhexanoic acid, pharmaceutical secondary standard; certified reference material
hexanoic acid,2-ethyl-, tridecyl ester
2-ethylhexanoicacid
alpha-ethylhexanoic acid
2-ethyl-hexonic acid
CS-W016381
Q209384
SB44987
SB44994
Z104478072

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" 2-EHA was marginally toxic to the dams at 600 mg/kg, but not at lower doses, since the mean near term body weight was reduced by 11%."( The developmental toxicity of 2-ethylhexanoic acid in Wistar rats.
Huuskonen, H; Komulainen, H; Pennanen, S; Tuovinen, K, 1992
)
0.57
" No adverse effects of treatment were associated with the lower 2-EHA doses (100 and 125 mg/kg/day)."( Assessment of the developmental toxicity of 2-ethylhexanoic acid in rats and rabbits.
Fisher, LC; Fosnight, LJ; Hendrickx, AG; Katz, GV; Kubena, MF; Peterson, PE; Tyl, RW; Vrbanic, MA, 1993
)
0.55
" In the present work the effects of developmentally toxic doses of 2-ethylhexanoic acid (EHXA), 2-ethylhexanol (EHXO), and valproic acid (VPA) on Zn metabolism were investigated in the pregnant rat."( Altered zinc metabolism contributes to the developmental toxicity of 2-ethylhexanoic acid, 2-ethylhexanol and valproic acid.
Bui, LM; Commisso, JF; Faber, WD; Keen, CL; Taubeneck, MW; Uriu-Hare, JY, 1998
)
0.77
" Dams tolerated the applied dose levels without any toxic effects."( Developmental toxicity of 2-ethylhexyl stearate.
Aulmann, W; Bartnik, F; Kästner, W; Pittermann, W; Potokar, M; Sterzel, W, 2000
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analyses for each of the enantiomers were performed in maternal plasma, maternal muscle, and embryo."( Murine teratology and pharmacokinetics of the enantiomers of sodium 2-ethylhexanoate.
Collins, MD; Evans, DA; Miller, SJ; Nau, H; Scott, WJ, 1992
)
0.28
" On the other hand, the peak concentration and duration of exposure to valproic acid and ethylhexanoic acid were very similar despite a more severe teratologic outcome following valproic acid, which indicated higher intrinsic activity of this latter agent."( Pharmacokinetic determinants of embryotoxicity in rats associated with organic acids.
Collins, MD; Nau, H; Scott, WJ, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
"The dose-response relationships for peroxisome proliferation due to Di (2-ethylhexyl) adipate (DEHA), 2-ethylhexanol (EH), 2-ethylhexanoic acid (EHA) have been investigated in rats and mice."( Peroxisome proliferation due to di (2-ethylhexyl) adipate, 2-ethylhexanol and 2-ethylhexanoic acid.
Canning, PM; Cornu, MC; Elcombe, CR; Foster, J; Keith, Y; Lhuguenot, JC, 1992
)
0.72
"1 g/kg) oral doses of [2-14C-hexyl]EHA, following repeated oral dosing with unlabelled EHA and a final [14C]EHA oral dose at the low dose level, following dermal exposure with a high (1 g/kg) and low (0."( Metabolism of 2-ethylhexanoic acid administered orally or dermally to the female Fischer 344 rat.
Deisinger, PJ; English, JC; Guest, D, 1998
)
0.66
" For developmental toxicity this requires scaling the in vitro observed dose-response characteristics to in vivo fetal exposure, while integrating maternal in vivo kinetics during pregnancy, in particular transplacental transfer."( Integrating in vitro chemical transplacental passage into a generic PBK model: A QIVIVE approach.
Fragki, S; Hoogenveen, R; Piersma, AH; Schwillens, P; van Oostrom, C; Zeilmaker, MJ, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
branched-chain fatty acidAny fatty acid in which the parent hydrocarbon chain has one or more alkyl substituents; a common component in animal and bacterial lipids. The fatty acyl chain is usually saturated and the substituent a methyl group; however, unsaturated BCFAs are found in marine animals, and branches other than methyl are found in microbial lipids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency28.18380.000221.22318,912.5098AID588515
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.32270.000229.305416,493.5996AID743075
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency31.62283.548119.542744.6684AID743266
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.10000.039816.784239.8107AID995
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)Ki450.00000.00001.372610.0000AID589727
Carbonic anhydrase 2Homo sapiens (human)Ki93.00000.00000.72369.9200AID589728
Solute carrier family 22 member 20Mus musculus (house mouse)Ki6.60351.10006.67899.1201AID360149
Solute carrier family 22 member 6Mus musculus (house mouse)Ki56.61710.40745.02179.4000AID360150
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID589732Selectivity ratio of Ki for human cytosolic carbonic anhydrase 2 to Ki for Candida albicans Nce103 beta-carbonic anhydrase2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID589728Inhibition of human cytosolic carbonic anhydrase 2 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
AID589730Inhibition of Candida albicans Nce103 beta-carbonic anhydrase by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
AID589729Inhibition of Cryptococcus neoformans Can2 beta-carbonic anhydrase by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID589731Selectivity ratio of Ki for human cytosolic carbonic anhydrase 2 to Ki for Cryptococcus neoformans Can2 beta-carbonic anhydrase2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
AID589727Inhibition of human cytosolic carbonic anhydrase 1 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (72)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (11.11)18.7374
1990's26 (36.11)18.2507
2000's20 (27.78)29.6817
2010's13 (18.06)24.3611
2020's5 (6.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.04 (24.57)
Research Supply Index4.36 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index105.08 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.30%)6.00%
Case Studies1 (1.30%)4.05%
Observational0 (0.00%)0.25%
Other75 (97.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]